VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA’s Coronavirus Treatment Acceleration Program (CTAP)
- Monday, May 18, 2020, 7:15
- Environment
- Add a comment
SOUTH SAN FRANCISCO, Calif., May 18, 2020 /PRNewswire/ — VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety and depression, as well as certain central nervous system (CNS) diseases and disorders with high unmet…
About the Author
adminasapcorp has written 41794 stories on this site.